Abstract
Biological agents are highly effective in preventing/minimizing disability related to multiple sclerosis. However, in resource-limited countries, the diagnosis and management of multiple sclerosis are limited by social and structural determinants of health. Support for patients to access these medicines through government schemes or insurance coverage is important in preventing disability.